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ABSTRACT
Objectives: Periodical assessments of population susceptibility to polioviruses (PV) is essential for
evaluating population protection and planning appropriate vaccination strategies. The aim of the current
work was to assess serological protective titers against all three polioviruses in the general population of
Florence. Methods: A convenience sample of 328 sera, collected in 2009 in Florence (Central Italy) was
analyzed. Samples were considered protective if neutralizing antibodies were detected at dilutions 1:8,
according to the WHO protocols. Results: The immune coverage was 75.3%, 69.2% and 46% for PV1, PV2
and PV3, respectively. The protective titers of neutralizing antibodies were generally higher in children up
to 14 years of age, with 74.4% (PV1), 75.6% (PV2) and 56.7% (PV3) of seroprevalence. From the age of
11 years, most of the study subjects were seronegative for PV3. Conclusions: In a polio-free country with
strong migration pressures, such as Italy, our results bring clear support to the recent recommendation of
Italian health authorities to introduce a fifth dose of IPV vaccine in adolescence all over the country.
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Introduction
Poliomyelitis is an acute communicable disease caused by any
of 3 poliovirus serotypes (PV1, PV2 or PV3). Poliomyelitis was
until a recent past a devastating disease in terms of morbidity
and mortality in Italy, as well as in the rest of the world.1 Start-
ing from 1988 the World Health Organization (WHO) has
engaged an all-out struggle for the eradication of the three
polioviruses worldwide through the extensive spread of vacci-
nation. When the eradication campaign started the global inci-
dence of poliomyelitis was >350,000 cases per year, with 125
endemic countries.2
At the end of 2015, only two countries, Afghanistan and
Pakistan, were considered endemic for poliomyelitis, but fol-
lowing the report in August 2016 of four cases of paralysis due
to WPV1 in Borno state (northern Nigeria) Nigeria lost its
“non-endemic” status.3
Overall, in 2017, only 22 cases of WPV1 infection have been
reported to WHO (8 in Pakistan and 14 in Afghanistan), com-
pared with 37 cases in 2016 and 74 cases in 2015, but a total of
91 circulating vaccine-derived poliovirus type 2 (cVDPV2)
cases were officially reported (17 in the Democratic Republic of
the Congo (DRC) and 74 in Syria).2 As of 24 January, in 2018 a
single case of type 1 wild poliovirus (WPV1) was confirmed in
Afghanistan and no cVDPV2 cases were reported.
The type 2 wild poliovirus (WPV2) has been isolated for the
last time in 1999 and declared eradicated on September 2015.
The wild type poliovirus 3 (WPV3) has not been isolated in polio
cases for more than five years (most recent case in November
2012). These figures raise hopes for a near future without polio.
Salk inactivated vaccine (IPV) is generally adopted in polio-
free countries with low risk of importation of wild Polioviruses
to rule out the risk of generating live attenuated oral polio vac-
cine (Sabin vaccine or OPV)-derived virus strains through cir-
culation in human populations with deficient herd immunity.
In order to eliminate OPV vaccine-related disease burden, also
in countries in which poliomyelitis cases are still notified, the
switch from trivalent to bivalent OPV vaccine (containing type
1 and 3 polioviruses only) has been implemented starting from
April 2016. However, to maintain immunity level to PV2 the
introduction of at least one dose of IPV into routine immuniza-
tion schedule was planned in 2017 in high risk countries.1,4
In Italy, as in the rest of the world, vaccination strategies
have changed over time following vaccine development and
epidemiological evolution of the disease. The Salk vaccine has
been introduced in Italy in 1957 and it has been replaced by
Sabin vaccine in 1964. After the introduction of Sabin vaccine,
the number of reported cases quickly dropped from an average
of more than 3,000 per year during 1960–64 to 254 in 1965 and
147 in 1966, when polio vaccination became mandatory.5
Poliomyelitis incidence further declined rapidly during the ‘70s
and the last indigenous case was registered in Italy in 1982.
During the ‘80s three imported cases, one each from Iran, India
and Libya, have been reported. Thereafter, only a few vaccine-
associated poliomyelitis cases were notified.6 From 1999 to
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2002 a sequential schedule with two doses of IPV followed by
two doses of OPV was adopted, to be replaced at the achieve-
ment of the eradication of poliomyelitis in the European region
in 2002 by an IPV-only schedule.7 Since 2005 the offer of the
fourth dose has been postponed from the 3rd to the 5th year of
life.8 In Tuscany, the schedule shift was completed in 2007.9-11
According to the current epidemiological data the overall
surveillance of polio disease should be based on three corner-
stones. The first issue concerns the control of faeces/stool in
the environment, through the monitoring of poliovirus pres-
ence in untreated municipal sewage, both in endemic areas and
in polio-free areas for the possible reappearance of wild clones.
This was clearly demonstrated in 2013 in Israel, where IPV-
only vaccination had been implemented starting from 2005.
The reintroduction and wide circulation in the population of
WPV1 was detected by environmental surveillance at sewage
treatment plants but no clinical cases were signaled.12 The sec-
ond issue is a continuing surveillance of flaccid paralysis in
order to identify unexpected diseases due to wild or vaccine-
derived polioviruses.
Of course, the third issue relies on the extensive spread of
vaccination. Actually, the attainment of the herd immunity and
its maintenance have determined the essential requirement for
the disappearance of the disease and the eradication of the three
viruses. On the other hand, suboptimal vaccination coverage,
due to many causes, may be responsible for the reintroduction
of wild polioviruses in populations declared for many years
polio-free, as occurred in the epidemic of 2013 in Syria due to
viruses imported from Pakistan.13
The Italian Ministry of Health reported >95% average
national immunization coverage rate at 24 months of age
against poliovirus until 2013, but unfortunately in the following
years values have decreased below 95%. According to the last
available data, in 2016 the average national immunization cov-
erage against poliovirus has dropped to 93.3% and this trend
leads to some concern.14
The presence in blood of neutralizing antibodies against
polioviruses indicates protective immunity and is an excellent
correlate of protection against paralytic disease.15 Herd immu-
nity is the indirect protection to susceptible subjects conferred
by immune individuals in the population. One of the objectives
of vaccination programs is to achieve appropriate vaccination
coverage to establish the necessary herd immunity, thus pre-
venting outbreaks.16 Herd immunity is established in a popula-
tion when the prevalence of protected individuals (vaccinated
or naturally infected) is higher than a critical value (herd
immunity threshold). The assessment of this threshold depends
on various factors: vaccine effectiveness of the immunization
program in the community; sensitivity and specificity of sero-
logical tests used to assess the prevalence of protected popula-
tion. It is estimated that the herd immunity threshold for
poliovirus is obtained at a minimum level of vaccination cover-
age equal to 80%-86%. In population groups without herd
immunity, additional vaccinations are necessary to increase
immunity levels and create herd immunity in the population.17
Therefore, seroprevalence studies are fundamental, especially if
repeated over time, to provide relevant information on the level
of immunity induced by the vaccine and to assess the persis-
tence of herd immunity in vaccinated population.
The main aim of the current work was to assess the serologi-
cal protective titer against all three polioviruses in a sample of
sera collected in 2009 from subjects residing in Florence (Cen-
tral Italy).
Results
As assessed by neutralization tests, the immune coverage calcu-
lated on the whole population studied was 75.3%, 69.2% e 46%
for PV1, PV2 and PV3, respectively. Protective titers of neutral-
izing antibodies against PV1 were detected in 74.4% of the
pediatric samples (0-14 years of age) and in 78.8% and 80.3%
of the people aged 15–43 and 44–65 years, respectively. A
reduction to 66.2% was demonstrated in adults over 65 years
old. Less than a half (44.4%) of the 9 children under one year of
life, including unvaccinated newborns eventually profiting of
maternal immunity and infants likely partly immunized (1 or 2
doses), had an immune coverage for PV1. A protective titre for
PV1 was found in 85.7% of the sera in the 1–4 years age group
but seroprevalence percentages decreased to 58.8% in subjects
5–7 years old, to rise again at 80% or more in those aged 8–
14 years (Fig. 1a). Immune protection for PV2 fluctuated from
a maximum of 75.6% in children aged 0–14 years to a mini-
mum of 61.8% in the over 65 but was higher (76.1% vs 63.6%)
in the 44–65 years age group than in the presumably vaccinated
15–43 years old subjects. Only 22.2% of children under one
year of life showed an immune protection for PV2. In the 1–
4 years old immune protection from PV2 was found in 90.5%
of sera, but lowered to 52.9% in the 5–7 years age group,
reached a 100% top in those aged 8–10 years and then
decreased to 78.3% in the 11–14 years age group (Fig. 1b). All
age-groups analyzed showed a lower prevalence of protective
antibodies against PV3 than against PV1 and PV2 (Table 1).
The lowest immune coverage for PV3 was found in children
under one year of life (22.2%). Immune protection for PV3
reached 76.2% of sera in the 1–4 years group, decreased to
52.9% in the 5–7 years age group, climbed to 75% in those aged
8–10 years and dropped again to 39.1% in the 11–14 years age
group. The percentage of PV3 protective sera remained
between 38% and 45% in the older age groups (Fig. 1c).
The geometric mean titers (GMTs) of neutralizing antibod-
ies for PV1, PV2 and PV3 were also analyzed. As expected, the
highest GMTs were observed in the pediatric age groups (0-14
years), 36.2, 72.1 and 63.3, respectively for PV1, PV2 and PV3,
with wide variations between age sub-groups. Titers dropped to
28.1, 28.1 and 21.6, respectively, among subjects aged
15–43 years (p < 0.05). Subjects aged 44–65 years had antibody
titers higher than those found in 16–43 years old (p < 0.05).
Children under 11 years showed higher GMTs for PV2 and
PV3 than for PV1. However, antibody levels against PV1
remained almost constant in all the four age groups analyzed,
while immunity against PV2 and PV3 decreased sharply
already in the 11–14 age group but was at its lowest also in the
15–43 years old (Table 1).
Serum samples able to neutralize simultaneously all three
polioviruses (triple-positive) were found in 37.5% of the whole
pediatric population but a progressive reduction from 76.2% in
children 1–4 years old to 34.8% in the 11–14 years old
(p < 0.01) was observed. Conversely, the rate of triple-negative
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samples in children was very low (9.5%) in the 1–4 years old,
increased to 41.2% in the 5–7 years old and then decreased
again to less than 13% in the 11–14 age group (Table 1). In
adults, the prevalence of triple-positive samples decreased from
more than 30% in the 15–65 years age groups, to 23.5% in the
over 65, while triple-negatives fluctuated in the range 8.5%-
14.7% (Table 1).
Discussion
The evaluation of protective immunity against polioviruses,
performed on sera collected in 2009 from subjects residing
in the Florentine area (Tuscany, Central Italy) demonstrated
that, in spite of high national immunization coverage rate
against polioviruses for many decades, a low immune pro-
tection was found in children and young people in the Flor-
ence area, especially for PV3. Apparently, the antibody
levels against PV3 rapidly decrease during childhood and
most of the presumably vaccinated subjects became sero-
negative by the age of 15. The results of the analysis of the
sera belonging to the pediatric age groups demonstrated
that after the completion of the basic four-doses vaccination
course a substantial response, although not optimal, is
observed against all three polioviruses. However, part of the
population quickly lost protective immunity against PV2
and a much higher percentage of sera without evidence of
protection was observed for PV3.
The early loss of protective immunity and/or low GMTs in
adolescents and young adults, mainly for PV3 but also for PV1,
have already been reported in recent years elsewhere in Italy
and in some European countries.18-25 A previous seropreva-
lence survey on pediatric sera (0–14 years) collected from the
Florentine hinterland in the period 2005–2006 showed a pro-
tective coverage for the three polioviruses significantly higher
compared to the current survey (93.2%, 94.3% and 90.9%,
respectively for PV1, PV2 and PV3). However, also in the
2005–2006 survey the level of immune coverage for PV3 was
the lowest and protective antibodies levels against PV3
decreased starting from the twelfth year of age.26 The lack of
booster effect due to the eradication of wild type polioviruses
and to the implementation of IPV-only vaccination are possibly
responsible for the general reduction in protective antibody
titers in children and young adults. The 2002 switch to the
IPV-only schedule could eventually explain the lower protec-
tion levels found in the pediatric population of Florence in
2009 when compared to the previous survey in 2005–2006,
when the pediatric population was supposed to have received
at least two doses of OPV.26
Figure 1. Poliovirus immune coverage rate for PV1 (a), PV2 (b) and PV3 (c) in the
whole sample of sera, collected in 2009 in Florence (Tuscany, Central Italy), strati-
fied in sub-groups according to polio vaccination schedule administered. [d: dose;
IPV: Inactivated poliovirus vaccine; OPV: Oral poliovirus vaccine].
Table 1. Serum samples tested for each age group and sub-group. Prevalence and Geometric Mean Titers (GMTs) of protective antibodies  1:8 against polio 1 (PV1),
polio 2 (PV2) and polio 3 (PV3) viruses in sera collected in 2009 in Florence (Tuscany, Central Italy). Prevalence of triple positive and triple negative samples is also shown.
% of protective antibodies ( 1:8) GMTs
Age group (years) Age sub-group (years) No. tested samples PV1 PV2 PV3 PV1 PV2 PV3 % Triple positive % Triple negative
0–14 90 74.4 75.6 56.7 36.2 72.1 63.3 52.2 18.9
<1 9 44.4 22.2 22.2 29.8 192 256 22.2 55.6
1–4 21 85.7 90.5 76.2 35.6 81.2 111.5 76.2 9.5
5–7 17 58.8 52.9 52.9 40.8 189.2 155.3 52.9 41.2
8–10 20 80 100 75 44.3 70.6 34 60 0
11–14 23 82.6 78.3 39.1 32.5 39.7 19.6 34.8 13
15–43 99 78.8 63.6 38.4 28.1 28.1 21.6 30.3 14.1
44–65 71 80.3 76.1 45.1 34.5 45.1 29.3 33.8 8.5
>65 68 66.2 61.8 44.1 47.2 42.7 36.7 23.5 14.7
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The lower protection we detected in the 5–7 years old group
with respect to the 8–10 group, both theoretically exposed to 4
vaccine doses, could indicate a longer lasting immunity induced
by the sequential IPV-OPV schedule (Table 1 and Fig. 1).
In Tuscany, a study conducted in 1963,27 before mass vacci-
nation was implemented, reported the simultaneous presence
of antibodies against PV1, PV2 and PV3 in 50% of healthy chil-
dren aged 1–5 years and in 76% of the 21–22 years old. Anti-
bodies against PV2 appeared earlier in children and they were
more frequently detected also reaching the highest titers in
the whole population. Similar findings were reported in the
same years in Southern Italy.28 The wide circulation of wild
polioviruses could explain the high prevalence of protective
anti-polio antibodies we found in our study in subjects born
before the introduction of compulsory vaccination in 1966.
Consistently, the detection of higher antibody levels for all
three polio types in subjects aged 44–65 years than in younger
people was probably due to several expositions to wild type
and/or vaccine polioviruses circulating in the population and
acting as boosters for immunity. The reduction of antibodies
titers in the over 65 years old that were exposed to the same
boosters opportunities of the preceding age-group could merely
correlate to their immune senescence.
Although there is no evidence that loss of detectable anti-
bodies puts at risk of disease immunocompetent vaccinees,1in
the absence of natural boosters, IPV recipients will remain sus-
ceptible to poliovirus infection. IPV vaccination alone is insuffi-
cient to induce a mucosal IgA response against poliovirus. In
mucosally (OPV-) primed individuals, however, booster vacci-
nation with IPV leads to a strong mucosal IgA response.29
Declining protective immunity in the Italian population might
favor silent transmission of neurovirulent polioviruses to
unvaccinated subjects. Although there is no indication that vac-
cination with IPV only confers lower levels of immune protec-
tion than provided by the sequential IPV-OPV or by the OPV-
only schedule,1 IPV-only schedules permit WPV transmission,
even at high IPV vaccination coverage, as demonstrated by the
persistent circulation of WPV in Israel in 2013.30
In the years of birth of the pediatric cohort analyzed in the
present study the poliovirus vaccination coverage in the Floren-
tine pediatric population was inferred from the Regional cover-
age level in Tuscany that remained stable at around 96%.31
This study has some limitations. First, the serum samples
analyzed belonged to a collection stored in 2009, thus the prev-
alence of protection reflected the serological profile of the pop-
ulation at that time. Second, according to the Italian Data
Protection Act, only limited data elements were collected and it
was not possible to determine vaccination status. Third, our
results were representative of a restricted geographical area.
Larger seroprevalence surveys, involving a nationally represen-
tative sample population, including recent immigrants, are
needed to update the Italian sero-epidemiological situation.
The introduction of a fifth IPV dose in adolescence is
intended to raise protective antibody titers and to extend pro-
tective immunity.32 Moreover, a single IPV dose has been dem-
onstrated to boost and maintain at high levels mucosal IgA
response in previously OPV-vaccinated persons.29 Some Euro-
pean Countries, such as United Kingdom, France and Germany
have already introduced the fifth polio dose into their
vaccination schedule.33 Its geographical position puts Italy at
high risk for polioviruses importation. Therefore, the Italian
Ministry of Health recently officially recommended the admin-
istration of a fifth IPV dose in adolescents and the new schedule
has already been implemented by some regional health
authorities.34
In order to counter the gradual decline in vaccinations
observed in Italy since 2013, the Italian Ministry of Health
extended to ten (including IPV) the panel of mandatory vacci-
nations for preschool and school-age children and for adoles-
cents up to 16 years, starting from September 2017.35 Other
European countries have already approved mandatory vaccina-
tions.36 A new policy in France requires all children born Janu-
ary 2018 or later to receive 11 mandatory vaccines.37
Conclusions
Further surveys, would be necessary to confirm our observa-
tions and to better explain the apparent loss of vaccine-induced
immunity observed in the Florentine population in recent
years. However, our results encourage to introduce into the
national vaccination schedule a fifth IPV dose in adolescence,
in order to obtain a longer-lasting immunity in the population.
Seroprevalence studies provide valuable information to assess
the levels of protection against diseases in a population and
suggest to maintain a state of attention against this specific dis-
ease also in countries, like Italy, where polio cases have not
been notified since many decades. Italy and the other European
countries are fully committed to prepare the global objective of
a Polio-Free World with all available measures.
Materials and methods
Study population
The evaluation of immunity against PV1, 2 and 3 was carried
out on a population of 328 immunocompetent subjects, 161
females and 167 males aged 0 to 88 years (mean age 38 years,
Table 2. Type of vaccine and vaccine doses supposedly administered to the pedi-
atric cohort of subjects (up to 14 years) included in the seroprevalence survey of
sera collected in Florence (Tuscany, Central Italy), 2009, according to the vaccina-
tion offer recommended.
Year of
birth
Age
(years)
Doses of Polio vaccines
received at the time of
2009a
Type of Polio vaccine
administered
Age at 4th
dose (years)
1995 14 4 OPV 3
1996 13 4 OPV 3
1997 12 4 OPV 3
1998 11 4 OPV 3
1999 10 4 2IPV-2OPV 3
2000 9 4 2IPV-2OPV 3
2001 8 4 2IPV-2OPV 3
2002 7 4 IPV 3
2003 6 4 IPV 3
2004 5 4 IPV 3
2005 4 4 IPV 3
2006 3 3 or 4 IPV 3
2007 2 3 IPV 5
2008 1 2 or 3 IPV 5
2009 <1 None or <3 IPV 5
Note. aExpected according to the vaccination schedules recommended in Tuscany
over time; OPV: oral polio vaccine; IPV: inactivated polio vaccine.
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median age 35 years). Serum samples were collected in 2009
from the University Hospital Careggi and the Meyer Children’s
Hospital of Florence during routine general health and immu-
nological checkups. According to the Italian Data Protection
Act, only limited data elements (including initials, gender and
year of birth) were collected; therefore, it was not possible to
assess vaccination status. All samples were stored at -20C in
the serum bank of the serology laboratory of the Department of
Health Sciences, University of Florence. In Table 2 is reported
the expected number of polio vaccine doses administered to the
subjects included in the study, according to the evolution of the
Tuscan vaccination schedule in recent years, for the pediatric
birth cohort (0–14 years). The study population was divided
into four different age groups and five sub-groups for the pedi-
atric subjects, according to the vaccination offer recommended:
the first age group included children, from 0 to 14 years of age,
vaccinated with OPV and/or IPV (subjects up to 7 years
received only IPV vaccines, from none to four doses, on the
basis of their age at the moment of the sera sampling; subjects
belonging to the 8–10 years age group received a sequential
schedule of two IPV doses and two OPV doses and subjects
between 11 and 14 years of age received a whole OPV sched-
ule); subjects aged 15–43 years, born after the mandatory OPV
vaccination was introduced, were included in the second group;
the last two groups included probably unvaccinated adults,
aged from 44 to 65 years and over 65 years, respectively. The
distribution of sera samples into age groups is reported in
Table 1.
Serology
Neutralizing antibodies titers were determined at the Depart-
ment of Health Promotion Sciences and Mother and Child
Care "Giuseppe D’Alessandro”, University of Palermo, accord-
ing to the WHO protocols.38 Briefly, serum samples were com-
plement inactivated at 56C for 30 minutes and two fold
diluted to 1:1024. Dilutions from 1:8 to 1:1024 were placed in
contact (1 hour at 37C) with 100 TCID50 (50% tissue culture
infective doses) of the Sabin attenuated type 1, 2 and 3 strains
received from the Italian National Institute of Health, Rome.
Then, freshly trypsinized Vero cells were added. After 3–4 days
of incubation at 37C, the highest serum dilution that protected
50% of the cultures was recorded and samples were considered
protective if neutralizing antibodies were detected at dilutions
 1:8. Complying with the biocontainement requirements,
connected to the global withdrawal of the type 2 component of
OPV, all neutralization tests involving PV2 have been carried
out before April 2016.
Statistical analysis
The chi-square test was used to compare antibodies prevalence
and Student’s t-test to analyze differences in the geometric
mean titers (GMTs) calculated for each age group.
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